File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Levonorgestrel-releasing intrauterine system (Mirena®) and Depot medroxyprogesterone acetate (Depoprovera) as long-term maintenance therapy for patients with moderate and severe endometriosis: A randomised controlled trial

TitleLevonorgestrel-releasing intrauterine system (Mirena®) and Depot medroxyprogesterone acetate (Depoprovera) as long-term maintenance therapy for patients with moderate and severe endometriosis: A randomised controlled trial
Authors
Issue Date2010
PublisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/ANZJOG
Citation
Australian And New Zealand Journal Of Obstetrics And Gynaecology, 2010, v. 50 n. 3, p. 273-279 How to Cite?
AbstractBackground: Progestogen therapy has been found to be useful in controlling endometriosis. For patients after conservative surgery, long-term medical maintenance therapy should be sought to prevent recurrence and control symptoms. Levonorgestrel-releasing intrauterine system (LNG-IUS) may be a useful form of prolonged progestogen therapy for endometriosis. Aims: To evaluate and compare the efficacy and safety of LNG-IUS to depot medroxyprogesterone acetate (MPA) for patients with moderate or severe endometriosis following conservative surgery, in terms of symptoms control, recurrence prevention and patients' acceptance. Methods: A total of 30 patients after conservative surgery for endometriosis underwent randomisation. Of these patients, 15 received LNG-IUS and 15 had three-monthly depot MPA for three years. Their symptom control, recurrence, compliance and change in bone mineral density (BMD) were compared. The data were analysed using student's t-test and chi-square test. Results: Symptoms and recurrence were controlled by both therapies. The compliance was better in LNG-IUS Group with 13 patients staying on their therapy versus seven patients in Depot MPA Group. LNG-IUS users had a significantly better change in BMD (+0.023, +0.071 g/cm2) than Depot MPA users (-0.030, -0.017 g/cm2) in both hip and lumbar regions. Conclusions: Levonorgestrel-releasing intrauterine system was effective in symptom control and prevention of recurrence. LNG-IUS users showed a better compliance. After three years, bone gain was noted with LNG-IUS, but bone loss with depot MPA. © 2010 The Royal Australian and New Zealand College of Obstetricians and Gynaecologists.
Persistent Identifierhttp://hdl.handle.net/10722/184212
ISSN
2015 Impact Factor: 1.738
2015 SCImago Journal Rankings: 0.814
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, AYKen_US
dc.contributor.authorTang, LCHen_US
dc.contributor.authorChin, RKHen_US
dc.date.accessioned2013-06-25T03:01:25Z-
dc.date.available2013-06-25T03:01:25Z-
dc.date.issued2010en_US
dc.identifier.citationAustralian And New Zealand Journal Of Obstetrics And Gynaecology, 2010, v. 50 n. 3, p. 273-279en_US
dc.identifier.issn0004-8666en_US
dc.identifier.urihttp://hdl.handle.net/10722/184212-
dc.description.abstractBackground: Progestogen therapy has been found to be useful in controlling endometriosis. For patients after conservative surgery, long-term medical maintenance therapy should be sought to prevent recurrence and control symptoms. Levonorgestrel-releasing intrauterine system (LNG-IUS) may be a useful form of prolonged progestogen therapy for endometriosis. Aims: To evaluate and compare the efficacy and safety of LNG-IUS to depot medroxyprogesterone acetate (MPA) for patients with moderate or severe endometriosis following conservative surgery, in terms of symptoms control, recurrence prevention and patients' acceptance. Methods: A total of 30 patients after conservative surgery for endometriosis underwent randomisation. Of these patients, 15 received LNG-IUS and 15 had three-monthly depot MPA for three years. Their symptom control, recurrence, compliance and change in bone mineral density (BMD) were compared. The data were analysed using student's t-test and chi-square test. Results: Symptoms and recurrence were controlled by both therapies. The compliance was better in LNG-IUS Group with 13 patients staying on their therapy versus seven patients in Depot MPA Group. LNG-IUS users had a significantly better change in BMD (+0.023, +0.071 g/cm2) than Depot MPA users (-0.030, -0.017 g/cm2) in both hip and lumbar regions. Conclusions: Levonorgestrel-releasing intrauterine system was effective in symptom control and prevention of recurrence. LNG-IUS users showed a better compliance. After three years, bone gain was noted with LNG-IUS, but bone loss with depot MPA. © 2010 The Royal Australian and New Zealand College of Obstetricians and Gynaecologists.en_US
dc.languageengen_US
dc.publisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/ANZJOGen_US
dc.relation.ispartofAustralian and New Zealand Journal of Obstetrics and Gynaecologyen_US
dc.subject.meshAdulten_US
dc.subject.meshContraceptive Agents, Female - Therapeutic Useen_US
dc.subject.meshEndometriosis - Drug Therapy - Surgeryen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshLevonorgestrel - Therapeutic Useen_US
dc.subject.meshMedroxyprogesterone Acetate - Therapeutic Useen_US
dc.titleLevonorgestrel-releasing intrauterine system (Mirena®) and Depot medroxyprogesterone acetate (Depoprovera) as long-term maintenance therapy for patients with moderate and severe endometriosis: A randomised controlled trialen_US
dc.typeArticleen_US
dc.identifier.emailTang, LCH: lchtang@hku.hken_US
dc.identifier.authorityTang, LCH=rp01756en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1479-828X.2010.01152.xen_US
dc.identifier.pmid20618247-
dc.identifier.scopuseid_2-s2.0-77953833819en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77953833819&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume50en_US
dc.identifier.issue3en_US
dc.identifier.spage273en_US
dc.identifier.epage279en_US
dc.identifier.isiWOS:000278915200014-
dc.publisher.placeAustraliaen_US
dc.identifier.f10006106956-
dc.identifier.scopusauthoridWong, AYK=7403147449en_US
dc.identifier.scopusauthoridTang, LCH=7402081111en_US
dc.identifier.scopusauthoridChin, RKH=24358899900en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats